Pierre Fabre Medicament
Clinical trials sponsored by Pierre Fabre Medicament, explained in plain language.
-
New cell therapy takes on Epstein-Barr virus in patients with weak immune systems
Disease control OngoingThis study tests an experimental cell therapy called tabelecleucel in about 190 people with diseases caused by the Epstein-Barr virus (EBV). The treatment uses specially trained immune cells to attack EBV-infected cells. The main goal is to see if the therapy can shrink tumors or…
Phase: PHASE2 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated May 17, 2026 02:18 UTC
-
New drug targets tough cancers with BRAF/NRAS mutations
Disease control OngoingThis early-phase study tests an experimental drug called KIN-2787 in about 400 adults with advanced solid tumors (including lung cancer and melanoma) that have specific BRAF or NRAS gene mutations. The main goals are to check safety, find the best dose, and see if the drug can sh…
Phase: PHASE1 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated May 17, 2026 02:18 UTC
-
New hope for chinese lung cancer patients with rare gene mutation
Disease control OngoingThis study tests a combination of two targeted drugs, encorafenib and binimetinib, in Chinese adults with a specific genetic mutation (BRAF V600E) in advanced non-small cell lung cancer that has spread. Participants must not have received prior treatment with similar drugs. The g…
Phase: PHASE2 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated Apr 29, 2026 15:04 UTC